[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100584301":3},{"organization":4,"armGroups":7,"interventions":15,"overallOfficials":26,"centralContacts":30,"locations":39,"responsibleParty":58,"collaborators":60,"id":63,"slug":64,"hasResults":65,"nctId":66,"briefTitle":67,"officialTitle":67,"acronym":68,"eligibilityCriteria":69,"healthyVolunteers":70,"sex":71,"minAge":72,"maxAge":73,"enrollmentInfo":74,"targetDuration":21,"studyType":77,"phases":78,"briefSummary":80,"conditions":81,"keywords":21,"overallStatus":42,"whyStopped":21,"lastUpdateSubmitDate":83,"lastUpdatePostDateStruct":84,"startDateStruct":87,"completionDateStruct":89,"leadSponsor":91,"locationsCount":92},{"fullName":5,"class":6},"University of Birmingham","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"All participants","EXPERIMENTAL","All participants will receive the same interventions.",[13,14],"Diagnostic Test: ELISA","Diagnostic Test: Lateral flow assay",[16,22],{"type":17,"name":18,"description":19,"armGroupLabels":20,"otherNames":21},"DIAGNOSTIC_TEST","ELISA","Mpox-specific antibody ELISA",[9],null,{"type":17,"name":23,"description":24,"armGroupLabels":25,"otherNames":21},"Lateral flow assay","Dried blood spot lateral flow assay for Mpox antibody",[9],[27],{"name":28,"affiliation":5,"role":29},"Christopher Green","PRINCIPAL_INVESTIGATOR",[31,36],{"name":32,"role":33,"phone":34,"phoneExt":21,"email":35},"Shema Hugor","CONTACT","+250 791 207 333","h.shema@cleancooling.org",{"name":37,"role":33,"phone":21,"phoneExt":21,"email":38},"Karishma Gokani","k.gokani@bham.ac.uk",[40],{"facility":41,"status":42,"city":43,"state":21,"zip":44,"country":45,"countryCode":46,"cosmosGeoPoint":47,"geoPoint":52,"contacts":53},"Rwanda Biomedical Center","RECRUITING","Kigali","P.O. Box 7162","Rwanda","RW",{"type":48,"coordinates":49},"Point",[50,51],30.05885,-1.94995,{"lat":51,"lon":50},[54],{"name":55,"role":33,"phone":56,"phoneExt":21,"email":57},"Jean Pierre Musabyimana","+250788299096","jpierre.musabyimana@rbc.gov.rw",{"type":59,"investigatorFullName":21,"investigatorTitle":21,"investigatorAffiliation":21,"oldNameTitle":21,"oldOrganization":21},"SPONSOR",[61],{"name":62,"class":6},"Rwanda Biomedical Centre","100584301","mpox-comprehensive-assessment-for-responsive-immunisation-in-emergency-outbreaks-100584301",false,"NCT06887556","Mpox Comprehensive Assessment for Responsive Immunisation in Emergency Outbreaks","MPOX CARE","Inclusion Criteria:\n\n* Healthy males and females aged between ages 5-80 years, who are able and willing to provide informed consent and will comply with the study requirements.\n* Group 1 (suspected exposure cohort) only\n\n  * Live within or adjacent to an epidemiologically identified region of Mpox transmission\n  * Close contacts of those with microbiologically confirmed Mpox\n* Group 2 (post-exposure\u002Fvaccinated cohort) only\n\n  * Previous clinically or microbiologically confirmed Mpox or confirmed previous vaccination with a smallpox\u002FMVA vaccine\n  * Fully recovered from Mpox infection\n* Group 3 (control cohort) only:\n\n  * Asymptomatic with no known exposure to Mpox\n\nExclusion Criteria:\n\n* Unwilling or unable to provide informed consent to take part\n* Unwilling or unable to comply with study procedures\n* History of any suspected or confirmed disorder of the immune system that, in the opinion of the investigators, might impair the results of the study\n* Have a bleeding disorder deemed significant by a member of the study team\n* Pregnant or breast-feeding females\n* Group 1 (suspected exposure cohort) only\n\n  * Known history of Mpox infection\n  * Current symptoms consistent with Mpox\n  * Known exposure to Mpox in the last month\n* Group 2 (post-exposure\u002Fvaccinated cohort) only\n\n  * Participants with any ongoing symptoms of Mpox, indicating incomplete recovery.\n* Group 3 (control cohort only)\n\n  * Symptoms of Mpox\n  * Known exposure to Mpox in the last month",true,"ALL","5 Years","80 Years",{"count":75,"type":76},650,"ESTIMATED","INTERVENTIONAL",[79],"NA","The MPXV CARE study principally aims to use clinical and epidemiology data to target specific individuals willing and able to provide appropriate and proportionate biological samples to develop novel immune diagnostics that support models of disease burden and future vaccine utilisation.",[82],"Mpox","2025-03-19",{"date":85,"type":86},"2025-03-20","ACTUAL",{"date":88,"type":86},"2025-02-05",{"date":90,"type":76},"2026-12",{"name":5,"class":6},1]